Transthyretin Amyloidosis Treatment Market to Surpass US$ 1,218.3 Million Threshold by 2026

The Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) is expected to be valued at US$ 35.8 million in 2018 and is projected to exhibit a CAGR of 55.4% over the forecast period (2018–2026).

Launch of novel therapies indicated for the treatment of transthyretin amyloidosis is expected to propel growth of the market. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. launched ONPATTRO (patisiran) in Germany. The drug is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. In October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its novel drug TEGSEDI (inotersen) indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Key manufacturers in market have their novel therapies under development pipeline and are expected to gain approval in the near future. Presence of robust pipeline is also expected to be one the major factors driving the market growth. For instance, in March 2018, Pfizer, Inc. reported positive results from Phase 3 ATTR-ACT study of Tafamidis among patients suffering from transthyretin cardiomyopathy

Browse 35 Market Data Tables and 43 Figures spread through 221 Pages and in-depth TOC on Global Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Forecast to 2026

To know the latest trends and insights prevalent in the Global Transthyretin Amyloidosis Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/transthyretin-amyloidosis-treatment-market-687

Key players in the market are focused on strategic mergers and partnerships in order to enhance their market share. For instance, In October 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. entered into distribution agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts to distribute TEGSEDI (inotersen) subcutaneous injection for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. In August 2018, Alnylam Pharmaceuticals, Inc. partnered with US Bioservices, a specialty pharmacy and part of AmerisourceBergen, to dispense ONPATTRO (patisiran) lipid complex injection.

Transthyretin amyloidosis is a rare disease and its symptoms are not easily identified. It is therefore, diagnosed late, which in turn affects the course of action in terms of treatment. According to the data published by The American Journal of Managed Care in 2017, hereditary transthyretin-mediated (hATTR) amyloidosis affects around 50,000 patients worldwide. However, the diagnosis rate of disease is very low. According to the study published by Alnylam Pharmaceuticals, Inc., in January 2018, the diagnosis rate of hATTR in the U.S. is around ~10-30%, which is expected to be a major factor restraining growth of the market over the forecast period.

Key Takeaways of the Global Transthyretin Amyloidosis Treatment Market:

• The global transthyretin amyloidosis treatment market is expected to exhibit a CAGR of 4% over the forecast period, owing to product launches by manufacturers such as Alnylam Pharmaceuticals, Inc. and Ionis Therapeutics
• North America is expected to hold dominant position in the global transthyretin amyloidosis treatment market over the forecast period, owing to approval and launch of new products in the region. For instance, in June 2017, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Pfizer Inc.’s Tafamidis, the company’s investigational treatment therapy for Transthyretin Cardiomyopathy (TTR-CM).
• Asia Pacific is expected to witness significant growth in the market due increasing approvals of novel therapies in the region. For instance, in March, 2018, the Ministry of Health Labor and Welfare in Japan granted SAKIGAKE designation to Pfizer Inc.’s Tafamidis, for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• However, no approved drugs are available for the treatment of cardiomyopathy. Therefore, key players in the market are could focus on this opportunity to receive approval for their drugs for cardiomyopathy indication and can launch their drug in key region such as the U.S. to enhance their market share.
• Similar to cardiomyopathy, no specifically approved drug is available for the treatment of wild-type transthyretin amyloidosis. Therefore, key players could focus on this opportunity to develop drugs for the treatment of wild type disease to gain high revenue and market share.
• Major players operating in the global transthyretin amyloidosis treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.